Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

Post time 2024-3-29 19:04:42

journal：Alimentary Pharmacology & Therapeutics

Authors：Remo Panaccione; Silvio Danese; Wen Zhou; Justin Klaff; Dapo Ilo; Xuan Yao; Gweneth Levy; Peter D. R. Higgins; Edward V. Loftus; Su Chen; Yuri Sanchez Gonzalez; Carolyn Leonard; Xavier Hébuterne; James O. Lindsay; Qian Cao; Hiroshi Nakase; Jean‐Frédéric Colombel; Séverine Vermeire

Published date：2024-2-

DOI：10.1111/apt.17816

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.17816

Article link：http://dx.doi.org/10.1111/apt.17816

Article Source：Wiley。

Remark：

Post time 2024-3-29 19:04:43

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis